近年科研论文
(1)Zheng CQ, Liu M, Fan H*.Targeting complexes of super-enhancers as a promising strategy for cancertherapy. Oncology Let. 2020;21:
(2)Chen P, Qian Q, Zhu ZY, Shen XH, Yu SL, Yu ZH*, Sun R, Li YP, Guo DD, FanH*. Increased expression of EHMT2 associated with H3K9me2 levelcontributes to the poor prognosis of gastric cancer. Oncology Let. 2020; 20: 1734-1742
(3)Qian Y, Li Y, Zheng C, Lu T, Sun R, MaoY, Yu S, Fan H*, Zhang Z*. High methylation levels of histone H3lysine 9 associated with activation of hypoxia-inducible factor 1α (HIF-1α)predict patients' worse prognosis in human hepatocellular carcinomas. Cancer Genet. 2020; 245:17-26.
(4)Lin S, Zhou M, Li Y, Chen Y, Xu W, Xia W, Wang S, Yin R, Zhang Q, XuL*, Fan H*. H3K27 trimethylation and H3K9 dimethylation aspoor prognostic markers for patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2019; 12:2657-2664.
(5)SongW, Gu Y, Lu S, Wu H, Cheng Z, Hu J, Qian Y, Zheng Y, Fan H*.LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylatingH3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1complex. Cell Prolif. 2019; 52(4):e12621.
(6)ShenX, Gu Y, Yu S, Gong P, Mao Y, Li Y, Zheng Y, Qiao F, Zhao Z, Fan H*.Silenced PITX1 promotes chemotherapeutic resistance to 5-fluorocytosine andcisplatin in gastric cancer cells. ExpTher Med. 2019; 17:4046-4054.
(7)ZhouM, Li Y, Lin S, Chen Y, Qian Y, Zhao Z, Fan H*. H3K9me3,H3K36me3, and H4K20me3 Expression Correlates with Patient Outcome in EsophagealSquamous Cell Carcinoma as Epigenetic Markers. DigDis Sci. 2019,64:2147-2157.
(8)Lin SF，Zhou MH，Li YP，Chen YP， XuWZ，Xia WJ，Wang SW，Yin R，Zhang Q， XuL*，Fan H *. H3K27trimethylation and H3K9 dimethylation as poor prognostic markers for patientswith esophageal squamous cell carcinoma. Int J Clin ExpPatho. 2019;12: 2657-2664
(9)Gong P, Qiao F, Wu H, Cui H, Li Y, ZhengY, Zhou M,Fan H*.LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastriccancer. Cell Death Dis. 2018; 9:1158.
(10)Li Y, Guo D, Sun R, Chen P, Qian Q,Fan H*. Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate withPatient Outcome in Gastric Cancer.Dig Dis Sci. 2018;22. 5341-8.
(11)Wu H, Liu X, Gong P, Song W, Zhou M, Li Y, ZhaoZ, Fan H*. Elevated TFAP4 regulates lncRNA TRERNA1 to promote cell migration andinvasion in gastric cancer.Oncol Rep. 2018; 40:923-931.
(12)Qiao F, Gong P, Song Y, Shen X, Su X, Li Y, Wu H, Zhao Z,Fan H*. Downregulated PITX1 modulated bymiR-19a-3p promotes cell malignancy and predicts a poor prognosis of gastriccancer by affecting transcriptionally activated PDCD5.Cell Physiol Biochem. 2018; 46:2215-2231.
(13)Cui H, Hu Y, Guo D, Zhang A, Gu Y, Zhang S, Zhao C, Gong P, Shen X, Li Y,Wu H, Wang L, Zhao Z,Fan H*. DNA methyltransferase 3A isoform b contributes to repressing E-cadherinthrough cooperation of DNA methylation and H3K27/H3K9 methylation inEMT-related metastasis of gastric cancer. Oncogene. 2018; 37:4358-4371.
(14)Wu HZ，Hu Y, Liu XF, Song W, Gong PH, Zhang Kun, Chen ZX,Zhou MH, Shen XH, Qian YY, Fan H*.LncRNA TRERNA1 function as an enhancer ofSNAI1 promotes gastric cancer metastasis by regulating epithelial-mesenchymaltransition. Mol Ther Nucleic Acids. 2017; 8:291-299
(15)ZhaoZJ, Hu Y, Shen XH, Lao YB, Zhang LH, Qiu XM, Hu JJ, Gong PH, Cui H, Lu S, ZhengY, Zhou MH, Fan H*.HBxrepresses RIZ1 expression by DNA methyltransferase 1 involved in decreasedmiR-152 in hepatocellular carcinoma. Oncol Rep. 2017；21:2811-2818.
(16)Hu JJ, Song W, Zhang SD, Shen XH, Qiu XM,Wu HZ, Gong PH, Lu S, Zhao ZJ, He ML, FanH*.HBx-upregulated lncRNA UCA1promotes cell growth and tumorigenesis by recruiting EZH2 and repressingp27Kip1/CDK2 signaling. Sci Rep. 2016; 6:23521.
(17)Fan H*, ZhaoZJ, Cheng YC, Cui H, Qiao FC, Wang L, Hu JJ, Wu HZ, Song W. Genome-wideprofiling of DNA methylation reveals preferred sequences of DNMTs inhepatocellular carcinoma cells. Tumor Bio. 2016; 37:877-85.
(18)Cui H, Zhao C, Gong P, Wang L, Wu H, ZhangK, Zhou R, Wang L, Zhang T, Zhong S,FanH*. DNA methyltransferase 3Apromotes cell proliferation by silencing CDK inhibitor p18(INK4C) in gastriccarcinogenesis.Sci Rep. 2015; 5:13781.
(19)Zhao Z, Wang L, Song W, Cui H, Chen G,Qiao F, Hu J, Zhou R, Fan H*.Reduced miR-29a-3p expression is linked to the cell proliferation and cellmigration in gastric cancer. World J Surg Oncol. 2015; 13:101.
(20)Cui H, Wang L, Gong P, Zhao C, Zhang S,Zhang K, Zhou R, Zhao Z, Fan H*.Deregulation between miR-29b/c and DNMT3A Is Associated with EpigeneticSilencing of the CDH1 Gene, Affecting Cell Migration and Invasion in GastricCancer. PLoS One. 2015; 10:e0123926.
(21)Wu HZ, Zhang K, Pihai Gong PH, Qiao FC, WangL, Cui H, Sui XY, Gao JF, Fan H*.A novel functional tagSNP rs7560488 in the DNMT3A1 promoter is associated with susceptibility togastric cancer by modulating promoter activity., PLoS One. 2014；25：9:e92911
(22)Qiao F, Zhang K, Gong P, Wang L, Hu J, LuS, Fan H*. DecreasedmiR-30b-5p expression by DNMT1 methylation regulation involved in gastriccancer metastasis. Mol Biol Rep. 2014; 41:5693-700.
(23)Qiu XM, Zhang LH, Lu S, Song YW, Lao Y B,Hu JJ, Fan H*. Upregulationof DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNAmethylation. Oncol Rep. 2014；31: 202-208
(24)LaoYB, Wu HZ, Zhao CC, Wu QY, Qiao FC,FanH*. Promoter polymorphisms ofDNA methyltransferase 3B and risk of hepatocellular carcinoma. BiomedicalReports. 2013;1: 771-775.
(25)Zhao CC, Yan F, Wu HZ, Qiao FC, Qiu XM, Fan H*. DNMT3A -448A>Gpolymorphism and the risk for hepatocellular carcinoma. Biomedical Reports. 2013;1:664-668.
(26)Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, LiY, Zeng T, Hu J, Zhang L, Zhang L, FanH*. HBx-mediated miR-21 upregulation represses tumor-suppressorfunction of PDCD4 in hepatocellular carcinoma. Oncogene. 2013; 32, 3296– 3305
(27)Chen H, Pan Y, Cheng ZY, Wang Z, Liu Y, ZhaoZJ, Fan H.Hypermethylation and clinicopathologicalsignificance of RASAL1 gene in gastric cancer. Asian Pac J Cancer Prev. 2013;14:6261-5.
(28)Wu Q, Lu S, Wang L, HuJ, Qiao F, Qiu X, Zhao C, Lao Y, Song Y, FanH*. DNMT3A rs36012910 A>G polymorphism and gastric cancersusceptibility in a Chinese population. Mol Biol Rep. 2012; 39:10949-55.
(29)Fan H*, Chen L, Zhang F, Quan Y, Su X, QiuX, Zhao Z, Kong KL, Dong S, Song Y, Chan TH, Guan XY. MTSS1, a novel target ofDNA methyltransferase 3B, functions as a tumor suppressor in hepatocellularcarcinoma. Oncogene. 2012; 31:2298-308.
(30)Qiao F, Su X, Qiu X, Qian D, Peng X, Chen H,Zhao Z, Fan H*. Enforced expression ofRASAL1 suppresses cell proliferation and the transformation ability of gastriccancer cells. Oncol Rep. 2012;28:1475-81
(31)Zhao Z, Li C, Song Y, Wu Q, Qiao F, Fan H*. Association of theDNMT3A -448A>G polymorphism with genetic susceptibility to colorectalcancer. Oncol Lett. 2012; 3:450-454.
(32)Liu H, Jiao Y, Guan Y, Lao Y, Zhao C, Fan H*. The DNMT3B -579 G>Tpromoter polymorphism and risk of lung cancer. Exp Ther Med. 2012; 3:525-529.
(33)Huang H, Wei X, Su X, QiaoF, Xu Z, Gu D, Fan H, ChenJ. Clinical significance of expression of Hint1 and potential epigeneticmechanism in gastric cancer. Int J Oncol.2011; 38:1557-64.
(34)Yang J, Wei X, Wu Q, Xu Z, Gu D, Jin Y, ShenY, Huang H, Fan H, ChenJ. Clinicalsignificance of the expression of DNA methyltransferase proteins in gastriccancer. Mol Med Rep. 2011; 4:1139-43.
(35)Zhao ZJ, Wu QX, Chen J, Qiu XM, Zhang JQ, Fan H*. Depletion of DNMT3A suppressed cell proliferation and restoredPTEN in hepatocellular carcinoma cells. J Biomed Biotech. 2010; 2010:737535.
(36)Fan H*, Liu DS, QiuXM, Qiao FC, Wu QX, Su XW, Zhang F, Song YW, Zhao ZJ, Xie W.A functionalpolymorphism in the DNA methyltransferase 3A promoter modifies the susceptibility in gastriccancer but not in esophageal carcinoma.BMC Medicine. 2010；8:12
(37)Su XW, Lv CY, QiaoFC, Qiu XM, Huang WB, Wu QX, Zhao ZJ,FanH*. Expression pattern and clinical significance of DNAmethyltransferase 3B variants in gastric carcinoma. Oncol Rep.2010; 23:819-26.
(38)Yang X, Lee Y, Fan H, Sun X, Lussier YA.Identification of common microRNA-mRNAregulatory biomodules in human epithelial cancers. Chin Sci Bull. 2010; 55:3576-3589.
(39)Hu J, Fan H*, Liu D, Zhang S, Zhang F,Xu H. DNMT3B promoter polymorphism and risk of gastric cancer. DigDis Sci.2010; 55:1011-6.
(40)Qiu XM, Qiao FC,Su XW, Zhao ZJ, Fan H*.Epigenetic activation of E-cadherin is a candidate therapeutic target in humanhepatocellular carcinoma. Exp. Ther. Med. 2010; 1: 519-523.
(41)Fan H*, ZhaoZJ, Cheng J, Su XW, Wu QX, Shan YF. Overexpression of DNA methyltransferase 1 and itsbiological significance in primary hepatocellular carcinoma. WorldJ Gastroenterol.2009; 15:2020-6.
(42)Fan H*, LiuDS, Zhang SH, Hu JB, Zhang F, Zhao ZJ. The DNMT3B G>T promoterPolymorphism and the Risk of Esophagus Carcinoma in a Chinese Population.WorldJ Gastroenterol. 2008; 14:2230-4.
(43)Fan H*, Zhang F, Hu J, Liu D, Zhao Z.Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese:a case-control study. J Exp Clin Cancer Res. 2008; 27:24.
(44)Fan H*, Cheng J, Zhao ZJ.Inhibition of de novo DNA Methyltransferase3B is a Potential. Therapy for Hepatocellular Carcinoma. GastroenRes. 2008;1:33-39
(45)FanH*, Zhao Z, Quan Y, Xu J,Zhang J, Xie W.DNAmethyltransferase 1 knock down induces silenced CDH1 gene re-expression bydemethylation of methylated CpG in HCC cell line SMMC-7721. Eur JGastroenterol Hepatol. 2007; 19:952-61
(46)Fan H*, Zhao ZJ,Cheng YC, Shan YF, Lu ZH, Zhang JQ, Xie W. Analysis of gene induction andapoptosis in human hapetocellular carcinoma cells SMMC-7721 exposed to themethylation inhibitor 5-Aza-2’-deoxycytidine.Chin Med J (Engl). 2007; 120:1626-31
(47)Xu W, Fan H*, He X.LOI ofIGF2 is associated with esophageal cancer and linked to methylation status ofIGF2 DMR.J Exp Clin Cancer Res. 2006; 25: 543-7.
(48)Fan H*, Xu J, Zhao ZJ, ZhangJQ, Xie W. Construction of DNMT1 siRNA stable expressing construct andevaluation of its silenced efficiency in blocking gene expression.Chin J Med Genet, 2005; 22:142-145
(49)孙瑞，樊红*. 组蛋白赖氨酸甲基化修饰与胃癌发病机制相关性的研究进展. 东南大学学报医学版. 2019;38:536 – 540 （综述）
(50)王琼，陆向东，李懿萍，王楠瑶，黄娴婷，樊红*。 TRDMT1 蛋白在胃癌组织中的表达及其临床意义。 临床肿瘤学杂志， 2018；23（6）：524-527 (北图核心期刊)
(51)宋蕴薇，仇雪梅，陆森，樊红*. HBx抑制RASSF1A表达参与肝细胞癌发生的可能机制。 东南大学学报医学版， 2018；37（3）：401-406 （综述）
(52)吴华彰, 公丕海, 吴涛, 赵云利, 汤必奎, 陈文静, 刘牧林, 樊红*. 转录因子AP-4 基因真核表达载体构建及表达分析. 基因组学与应用生物学. 2018;38（5）(北图核心期刊)
(53)陈雨朦，刘琳，樊红。 LncRNA UCA1表达水平与常见肿瘤患者预后关系的研究进展。现代肿瘤医学杂志，2018；7：1135-1138 （综述）
(54)黄珊，于天源，樊红*。胃癌转移相关lncRNA的研究进展。东南大学学报（医学版） 2017；36: 1-4 （综述）
(55)宋伟，樊红*。胃癌中LncRNA的研究进展。 国际遗传学杂志2014；37:189-193（综述）
(56)张少丹，樊红*。组蛋白甲基化与lncRNAs的表达调控国际遗传学杂志2014；37:236-235（综述）
(57)杨华，樊红*。基于分子结构的lncRNA分子功能的研究进展。东南大学学报（医学版）2013；33：99-102（综述）
(58)石明，仇雪梅，樊红*。血浆miRNA检测在肿瘤临床应用的研究进展. 东南大学学报（医学版）。2012；31：122-125 （综述）
(59)崔鹤, 樊红* DNMT3A在肿瘤发生中表遗传调控作用的研究进展. 东南大学学报（医学版）。2012；31：508-511 （综述）
(60)吴华彰, 樊红*.Tag SNPs在鉴定肿瘤易感性基因研究中的应用. 东南大学学报(医学版)2013;31: 247-250 （综述）
(61)刘东声,张淑红,胡嘉波,张凤,赵主江, 樊红*.DNMT3B基因启动子C46359T多态性与食管癌易感性的关联分析东南大学学报 (医学版)2008; 27: 319-323
(62)单云峰，樊红*，赵主江等DNMT3B 基因异常表达与肝癌发生的相关性研究. 临床检验杂志 2008；26：27-30
(63)赵主江，樊红*，单云峰等. DNA甲基转移酶3AsiRNA真核表达载体的构建和鉴定. 东南大学学报（医学版）2008；27;1-5